Global reported endophthalmitis risk following intravitreal injections of anti-VEGF: a literature review and analysis
Authors:
Open Access
- 1 May 2015
- journal article
- review article
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 9, 773-781
Abstract
Purpose: To report on endophthalmitis occurrence and associated risk factors following the intravitreal injection of anti-VEGF agents based on a review of published literature. Materials and methods: A Medline search was performed using the terms “bevacizumab” and “ranibizumab”. A total of 534 English-language articles of varying design and published from 2006 to November 2013 were analyzed for endophthalmitis occurrence and contributing perioperative factors. Results: A total of 445,503 injections were counted. There were 103 cases of postinjection endophthalmitis in 176,124 injections (0.058%) with bevacizumab (Avastin) versus 79 cases in 269,379 injections (0.029%) with ranibizumab (Lucentis). This difference was due to a significantly higher occurrence of culture-negative endophthalmitis associated with bevacizumab injections. Culture-positive risk was not statistically different between the two drugs. The reported use of postinjection topical antibiotics increased the risk of culture-positive endophthalmitis. No association was found with the use of povidone iodine, a lid speculum, a mask, or an operating room. Streptococcus spp. were the most prevalent causative organism, accounting for nine of 54 (17%) of all culture-positive cases. Conclusion: Reported postinjection endophthalmitis occurred significantly more in patients treated with bevacizumab than those treated with ranibizumab. However, culture-positive occurrence was similar. Despite the potential for contamination at the time of drug compounding, bevacizumab does not appear to confer a higher risk of culture-positive endophthalmitis than ranibizumab. This study also suggests antibiotic use may increase endophthalmitis occurrence.Keywords
This publication has 27 references indexed in Scilit:
- Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser TreatmentOphthalmology, 2012
- Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular DegenerationOphthalmology, 2012
- Ranibizumab for Macular Edema Due to Retinal Vein OcclusionsOphthalmology, 2012
- Avastin Doesn't Blind People, People Blind PeopleAmerican Journal of Ophthalmology, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- INCIDENCE OF ENDOPHTHALMITIS RELATED TO INTRAVITREAL INJECTION OF BEVACIZUMAB AND RANIBIZUMABRetina, 2008
- INCIDENCE OF ACUTE ONSET ENDOPHTHALMITIS FOLLOWING INTRAVITREAL BEVACIZUMAB (AVASTIN) INJECTIONRetina, 2008
- Ranibizumab for Treatment of Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical StudyOphthalmology, 2005
- Maximum Tolerated Dose of a Humanized Anti–Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular DegenerationOphthalmology, 2005